文献速递胸部肿瘤

既往肺癌治疗后第二原发肺癌风险:SEER数据库分析

Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data.
PubMed 文献 · J Thorac Oncol · 2017-10-05

该研究回顾性分析SEER数据库1992至2007年数据,评估既往肺癌治疗后第二原发肺癌的发生频率并计算标准化发病比。结果显示第二原发肺癌发生率为每患者每年1.10%,累积风险随时间持续增加且未出现平台期,男女中位间隔分别为59和62个月。

要点

  • 第二原发肺癌发生率为每患者每年1.10%,累积风险随时间持续增加且未达平台期。
  • 男女第二原发肺癌的中位诊断间隔分别为59个月和62个月。
  • 年轻初发肺癌患者及女性(尤其20-49岁)的第二原发肺癌标准化发病比更高。

核心结论

  • 这些发现提示第二原发肺癌存在持续风险,需针对该人群制定监测策略。

研究设计与样本

  • 回顾性分析SEER数据库1992至2007年数据,评估第二原发肺癌发生频率并按人口学特征计算标准化发病比。

主要发现

  • 第二原发肺癌发生率为每患者每年1.10%,男女中位诊断间隔分别为59个月和62个月。
  • 男女各年龄段标准化发病比均高,初发肺癌年龄越轻则越高;女性各年龄和种族标准化发病比最高,20-49岁组SIR=15.26(95%CI 12.81-18.04)。
  • 第二原发肺癌累积风险随时间增加且未出现平台期。

关键数值与推荐

  • 第二原发肺癌发生率为每患者每年1.10%。
  • 男女第二原发肺癌与初发肺癌的中位诊断间隔分别为59个月和62个月。
  • 20-49岁女性第二原发肺癌SIR=15.26(95%CI 12.81-18.04)。

临床怎么用

  • 原文建议针对既往肺癌治疗后人群的监测策略需加以解决。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The risk for development of a second primary lung cancer (SPLC) after treatment of an initial primary lung cancer (IPLC) is around 1% to 2% per patient per year. The present screening and surveillance guidelines do not adequately address this particular patient population. METHODS: We retrospectively reviewed patients in the Surveillance, Epidemiology, and End Results database from 1992 to 2007 to assess the frequency of occurrence of SPLC with regard to multiple patient demographics and calculated standardized incidence ratios (SIRs). RESULTS: The SIRs for SPLCs were high for both men and women at any age but highest if the IPLC occurred at a younger age. Women had the highest SIR values irrespective of age and race, with the highest SIR reported for the youngest age group (20-49 years) (SIR = 15.26, 95% confidence interval: 12.81-18.04). The rate of SPLC development was 1.10% per patient per year, with median time intervals between the IPLC and SPLC diagnoses of 59 and 62 months, respectively, for men and women. The cumulative risk for development of SPLC increased over time and did not plateau. CONCLUSIONS: These findings suggest that there is a continued risk for development of SPLC. Surveillance strategies for this population must be addressed.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Thakur MK, Ruterbusch JJ, Schwartz AG, et al. Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data. J Thorac Oncol. 2017. PMID: 28989038. doi:10.1016/j.jtho.2017.09.1964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。